Johnson & Johnson (NYSE:JNJ) Stock Price Up 0% - Still a Buy?

Shares of Johnson & Johnson (NYSE:JNJ - Get Free Report) were up 0% during mid-day trading on Monday . The stock traded as high as $164.39 and last traded at $163.65. Approximately 1,244,081 shares changed hands during trading, a decline of 82% from the average daily volume of 7,066,249 shares. The stock had previously closed at $163.63.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on JNJ. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Wells Fargo & Company decreased their price target on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Argus raised Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $171.33.

Remove Ads

Johnson & Johnson Price Performance

The company has a market capitalization of $388.32 billion, a price-to-earnings ratio of 24.23, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The business has a 50-day moving average price of $157.70 and a two-hundred day moving average price of $156.14. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.29 earnings per share. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.08%. Johnson & Johnson's dividend payout ratio (DPR) is 74.59%.

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Institutional Investors Weigh In On Johnson & Johnson

Institutional investors have recently added to or reduced their stakes in the business. IFS Advisors LLC lifted its stake in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after buying an additional 100 shares in the last quarter. WealthTrak Capital Management LLC bought a new position in shares of Johnson & Johnson in the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at $29,000. Bay Harbor Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $32,000. Finally, Conquis Financial LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth about $33,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.